Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia

Clin Adv Hematol Oncol. 2019 Nov;17(11):604-606.
No abstract available

Publication types

  • Interview

MeSH terms

  • Ambulatory Care / methods*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Liposomes / chemistry
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / pathology
  • Treatment Outcome

Substances

  • Liposomes
  • Cytarabine
  • Daunorubicin